ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.789,26
0,03%
S&P 500
5.312,61
0,08%
US Dollar vs BRL
5,1069
0,05%
Bitcoin
70.216,85
-1,73%
Brent Oil
83,145
-0,46%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. Reino Unido
  5. LSE
  6. Immunovia Ab (publ) (0G8X)

  7. Immunovia Ab (publ) (0G8X) Notícias

0G8X

Immunovia Ab (publ) (0G8X)

Immunovia Ab (publ)
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:LSE:0G8X
DataHoraFonteTítuloCódigoCompanhia
04/01/202412:59PR Newswire (US)Immunovia announces financial calendar for financial year 2024LSE:0G8XImmunovia Ab (publ)
21/11/202307:40PR Newswire (US)Bulletin from the extraordinary general meeting in Immunovia ABLSE:0G8XImmunovia Ab (publ)
09/11/202305:03PR Newswire (US)Immunovia Publishes Interim Report for January-September 2023LSE:0G8XImmunovia Ab (publ)
07/11/202312:14PR Newswire (US)Immunovia successfully completes discovery phase of next-generation test developmentLSE:0G8XImmunovia Ab (publ)
02/11/202307:02PR Newswire (US)Invitation to Immunovia's Q3 presentationLSE:0G8XImmunovia Ab (publ)
27/10/202304:06PR Newswire (US)CONVENING NOTICE - EXTRAORDINARY GENERAL MEETING IN IMMUNOVIA AB (PUBL)LSE:0G8XImmunovia Ab (publ)
03/10/202306:01PR Newswire (US)Nomination Committee appointed for Immunovia AB (Publ)LSE:0G8XImmunovia Ab (publ)
30/08/202307:30PR Newswire (US)Immunovia Publishes Interim Report for January-June 2023LSE:0G8XImmunovia Ab (publ)
23/08/202315:08PR Newswire (US)Invitation to Immunovia's Q2 presentationLSE:0G8XImmunovia Ab (publ)
19/07/202313:47PR Newswire (US)Immunovia announces updated financial calendarLSE:0G8XImmunovia Ab (publ)
12/07/202304:15PR Newswire (US)Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer DetectionLSE:0G8XImmunovia Ab (publ)
09/06/202305:19PR Newswire (US)Chief Executive Officer, Jeff Borcherding, buys Immunovia sharesLSE:0G8XImmunovia Ab (publ)
31/05/202307:16PR Newswire (US)Change in number of shares and votes in Immunovia AB (publ)LSE:0G8XImmunovia Ab (publ)
26/05/202308:43PR Newswire (US)Bulletin from the Annual General Meeting in Immunovia ABLSE:0G8XImmunovia Ab (publ)
23/05/202304:03PR Newswire (US)Immunovia Publishes Interim Report for January-March 2023LSE:0G8XImmunovia Ab (publ)
22/05/202313:55PR Newswire (US)Changes to the Nomination Committee's proposal to the Annual General Meeting 2023 in Immunovia AB (publ)LSE:0G8XImmunovia Ab (publ)
17/05/202305:43PR Newswire (US)Invitation to Immunovia's Q1 presentationLSE:0G8XImmunovia Ab (publ)
06/05/202308:40PR Newswire (US)The board member Philipp von Hugo resigns from Immunovia's board at his own requestLSE:0G8XImmunovia Ab (publ)
30/04/202307:17PR Newswire (US)Immunovia AB appoints new CEOLSE:0G8XImmunovia Ab (publ)
26/04/202309:44PR Newswire (US)Immunovia to discuss adoption of IMMray™ PanCan-d with key opinion leaders on May 3, 2023LSE:0G8XImmunovia Ab (publ)
25/04/202304:02PR Newswire (US)CONVENING NOTICE - ANNUAL GENERAL MEETING IN IMMUNOVIA AB (publ)LSE:0G8XImmunovia Ab (publ)
21/04/202312:25PR Newswire (US)Immunovia publishes the annual report for 2022LSE:0G8XImmunovia Ab (publ)
20/04/202303:54PR Newswire (US)Immunovia to participate in National Pancreas Foundation Webinar on Biomarkers and Liquid Biopsy for Early Detection of Pancreatic CancerLSE:0G8XImmunovia Ab (publ)
12/04/202314:06PR Newswire (US)Immunovia announces outcome of the rights issueLSE:0G8XImmunovia Ab (publ)
17/03/202309:34PR Newswire (US)Immunovia publishes prospectus relating to the rights issueLSE:0G8XImmunovia Ab (publ)
01/03/202304:41PR Newswire (US)Immunovia appoints Karl Stone as new chief operating officer to develop R&D and operationsLSE:0G8XImmunovia Ab (publ)
23/02/202304:54PR Newswire (US)Immunovia Publishes Full Year Report for 2022LSE:0G8XImmunovia Ab (publ)
20/02/202311:37PR Newswire (US)Invitation to Immunovia's Q4 presentationLSE:0G8XImmunovia Ab (publ)
20/02/202304:44PR Newswire (US)CONVENING NOTICE - EXTRAORDINARY GENERAL MEETING IN IMMUNOVIA AB (publ)LSE:0G8XImmunovia Ab (publ)
20/02/202304:13PR Newswire (US)Immunovia resolves on a rights issue of approximately SEK 202.2 million and postpones the publication of the quarterly report for the first quarter and the annual general meetingLSE:0G8XImmunovia Ab (publ)
 Apresentando as notícias mais relevantes sobre:LSE:0G8X

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PDGR3
PDG REALT ON
BOV
HAGA3
HAGA ON
BOV
PRIO3
PETRORIO ON
BOV
SGPS3
SPRINGS ON
BOV
COGN3
COGNA ON
BOV
BHIA3
Grupo Casas Bahia ON
BOV
INBR32
Inter &
BOV
JHSF3
JHSF PART ON
BOV
LUPA3
LUPATECH ON
BOV
HBOR3
HELBOR ON
BOV
IFCM3
Infracommerce Caxaas ON
BOV
CASH3
Meliuz S.A ON
BOV
GOLL4
GOL PN
BOV
SEQL3
Sequoia Logistica e Tran... ON
BOV
MGLU3
MAGAZINE LUIZA ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados